JP6903648B2 - 切断高分子量キニノーゲンを検出するイムノアッセイ - Google Patents

切断高分子量キニノーゲンを検出するイムノアッセイ Download PDF

Info

Publication number
JP6903648B2
JP6903648B2 JP2018519871A JP2018519871A JP6903648B2 JP 6903648 B2 JP6903648 B2 JP 6903648B2 JP 2018519871 A JP2018519871 A JP 2018519871A JP 2018519871 A JP2018519871 A JP 2018519871A JP 6903648 B2 JP6903648 B2 JP 6903648B2
Authority
JP
Japan
Prior art keywords
hmwk
antibody
sample
subject
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018519871A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019502095A5 (oth
JP2019502095A (ja
Inventor
セクストン，ダニエル，ジェー．
フォーセット，ライアン
コシック，ジャニャ
Original Assignee
ダイアックス コーポレーション
ダイアックス コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダイアックス コーポレーション, ダイアックス コーポレーション filed Critical ダイアックス コーポレーション
Publication of JP2019502095A publication Critical patent/JP2019502095A/ja
Publication of JP2019502095A5 publication Critical patent/JP2019502095A5/ja
Priority to JP2021104359A priority Critical patent/JP7238027B2/ja
Application granted granted Critical
Publication of JP6903648B2 publication Critical patent/JP6903648B2/ja
Priority to JP2023031415A priority patent/JP7640599B2/ja
Priority to JP2025025949A priority patent/JP2025081553A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2018519871A 2015-10-19 2016-10-19 切断高分子量キニノーゲンを検出するイムノアッセイ Active JP6903648B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021104359A JP7238027B2 (ja) 2015-10-19 2021-06-23 切断高分子量キニノーゲンを検出するイムノアッセイ
JP2023031415A JP7640599B2 (ja) 2015-10-19 2023-03-01 切断高分子量キニノーゲンを検出するイムノアッセイ
JP2025025949A JP2025081553A (ja) 2015-10-19 2025-02-20 切断高分子量キニノーゲンを検出するイムノアッセイ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562243505P 2015-10-19 2015-10-19
US62/243,505 2015-10-19
US201662335311P 2016-05-12 2016-05-12
US62/335,311 2016-05-12
PCT/US2016/057640 WO2017070170A1 (en) 2015-10-19 2016-10-19 Immunoassay to detect cleaved high molecular weight kininogen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021104359A Division JP7238027B2 (ja) 2015-10-19 2021-06-23 切断高分子量キニノーゲンを検出するイムノアッセイ

Publications (3)

Publication Number Publication Date
JP2019502095A JP2019502095A (ja) 2019-01-24
JP2019502095A5 JP2019502095A5 (oth) 2019-11-28
JP6903648B2 true JP6903648B2 (ja) 2021-07-14

Family

ID=57233867

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018519871A Active JP6903648B2 (ja) 2015-10-19 2016-10-19 切断高分子量キニノーゲンを検出するイムノアッセイ
JP2021104359A Active JP7238027B2 (ja) 2015-10-19 2021-06-23 切断高分子量キニノーゲンを検出するイムノアッセイ
JP2023031415A Active JP7640599B2 (ja) 2015-10-19 2023-03-01 切断高分子量キニノーゲンを検出するイムノアッセイ
JP2025025949A Pending JP2025081553A (ja) 2015-10-19 2025-02-20 切断高分子量キニノーゲンを検出するイムノアッセイ

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021104359A Active JP7238027B2 (ja) 2015-10-19 2021-06-23 切断高分子量キニノーゲンを検出するイムノアッセイ
JP2023031415A Active JP7640599B2 (ja) 2015-10-19 2023-03-01 切断高分子量キニノーゲンを検出するイムノアッセイ
JP2025025949A Pending JP2025081553A (ja) 2015-10-19 2025-02-20 切断高分子量キニノーゲンを検出するイムノアッセイ

Country Status (17)

Country Link
US (2) US10914747B2 (oth)
EP (3) EP3365685B1 (oth)
JP (4) JP6903648B2 (oth)
KR (2) KR102698737B1 (oth)
CN (2) CN113655228B (oth)
AU (2) AU2016340826C1 (oth)
BR (1) BR112018007842A2 (oth)
CA (1) CA3002747A1 (oth)
CO (1) CO2018004289A2 (oth)
DK (1) DK3365685T3 (oth)
EA (1) EA201891002A1 (oth)
ES (2) ES2973301T3 (oth)
IL (2) IL258637B2 (oth)
MX (2) MX2018004763A (oth)
PL (2) PL3365685T3 (oth)
PT (1) PT3365685T (oth)
WO (1) WO2017070170A1 (oth)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2948479B1 (en) 2013-01-20 2018-08-01 Dyax Corp. Evaluation and treatment of bradykinin-mediated disorders
PT3060908T (pt) 2013-10-21 2021-05-27 Dyax Corp Diagnóstico e tratamento de doenças autoimunes
JP6757252B2 (ja) 2013-10-21 2020-09-16 ダイアックス コーポレーション 血漿カリクレイン系バイオマーカーを決定するためのアッセイ
CA3002747A1 (en) * 2015-10-19 2017-04-27 Dyax Corp. Immunoassay to detect cleaved high molecular weight kininogen
US11525002B2 (en) 2017-10-11 2022-12-13 Board Of Regents, The University Of Texas System Human PD-L1 antibodies and methods of use therefor
CA3092695A1 (en) 2018-03-23 2019-09-26 Board Of Regents, The University Of Texas System Human pd-l2 antibodies and methods of use therefor
EP3768726B1 (en) 2018-03-23 2024-10-30 Board of Regents, The University of Texas System Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
JP7514765B2 (ja) 2018-03-23 2024-07-11 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ヒトｐｄ－ｌ１およびｐｄ－ｌ２に対する二重特異性抗体およびその使用方法
KR20210025023A (ko) * 2018-06-26 2021-03-08 쿄와 기린 가부시키가이샤 콘드로이틴 황산 프로테오글리칸-5에 결합하는 항체

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1312564C (en) 1985-07-12 1993-01-12 Robert W. Colman Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same
US4908431A (en) 1986-01-22 1990-03-13 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human kininogen and methods of preparing same
US5047323A (en) * 1986-01-22 1991-09-10 Temple University Of The Commonwealth System Of Higher Education Method for detecting human kininogen using monoclonal antibodies thereto
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPS63185398A (ja) 1986-09-10 1988-07-30 Nippon Zoki Pharmaceut Co Ltd 生理活性物質測定法
US4882272A (en) 1986-10-01 1989-11-21 Temple University - Of The Commonwealth System Of Higher Education High molecular weight kininogen assay
US5025796A (en) 1988-12-01 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5472945A (en) 1991-08-13 1995-12-05 Temple University- Of The Commonwealth System Of Higher Education Modulation of blood pressure and inhibition of platelet activation with kininogen fragment
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
DE69533472T2 (de) 1994-01-11 2006-01-12 Dyax Corp., Cambridge Kallikreinhemmende "kunitz-domäne"-proteine und derivaten davon
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
JPH1084995A (ja) * 1996-09-12 1998-04-07 Nippon Zoki Pharmaceut Co Ltd 血液凝固第ｘｉｉ因子活性化法
US5789261A (en) * 1996-10-30 1998-08-04 Temple University Of The Commonwealth System Of Higher Education Solid phase immunoassay
US6242210B1 (en) 1997-05-20 2001-06-05 Actinova Limited Treatment of bacterial infections
JP4346798B2 (ja) * 1999-08-19 2009-10-21 協和メデックス株式会社 Ｈｃｖコア抗原の検出または定量方法およびそれに用いる検出または定量試薬。
US6994852B1 (en) 1999-11-12 2006-02-07 Temple University-Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
US7678541B2 (en) 2000-11-21 2010-03-16 Hologic, Inc. Methods and compositions for the detection of a nucleic acid using a non-invasive cleavage reaction
JP2002221519A (ja) * 2001-01-29 2002-08-09 Sysmex Corp 抗凝固剤およびそれを用いた抗凝固剤処理方法
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
US6913900B2 (en) * 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
DK2298278T3 (en) 2002-06-07 2016-02-01 Dyax Corp Prevention and reduction of blood loss and inflammatory response
WO2004005934A2 (en) 2002-07-04 2004-01-15 Oxford Glycosciences (Uk) Ltd Toxicity markers
US20070003552A1 (en) 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
CA2575791A1 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
PL1981519T3 (pl) 2005-12-29 2018-07-31 Dyax Corp. Hamowanie proteaz
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
EP2051707B1 (en) 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
EP2089712A4 (en) 2006-11-22 2010-09-22 Life Technologies Corp BIOMARKERS OF AUTOIMMUNE DISEASES
AU2008289005A1 (en) 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
EP2216651A4 (en) 2007-10-18 2010-12-01 Miyazaki Prefectural Ind Suppo BIOMARKERS FOR THE DIAGNOSIS OF LIVER DISEASE
EP2215256A1 (en) 2007-10-22 2010-08-11 Georg Dewald Disorders of vasoregulation and methods of diagnosing them
AU2009269257A1 (en) 2008-07-07 2010-01-14 Nippon Zoki Pharmaceutical Co., Ltd. Method for detection of fibromyalgia
WO2010062663A1 (en) 2008-11-03 2010-06-03 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
EP2369930A4 (en) 2008-12-02 2012-10-03 Joslin Diabetes Ct METHOD OF REDUCING BLOOD PRESSURE USING PLASMATIC KALLICREIN INHIBITORS
WO2010080833A1 (en) * 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
FR2942233B1 (fr) * 2009-02-19 2015-03-13 Lfb Biotechnologies Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre
KR101077275B1 (ko) 2009-05-07 2011-10-27 한국기초과학지원연구원 당단백질의 당쇄화를 이용한 암 진단 방법
JP5299179B2 (ja) 2009-09-02 2013-09-25 株式会社リコー 画像形成装置
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
AU2010330743A1 (en) 2009-12-18 2012-07-05 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
US9206123B2 (en) 2009-12-18 2015-12-08 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
WO2011085103A2 (en) 2010-01-06 2011-07-14 Dyax Corp. Plasma kallikrein binding proteins
WO2012009447A2 (en) 2010-07-13 2012-01-19 University Of Rochester THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF
EP2645932B1 (en) * 2010-12-02 2016-03-02 Becton, Dickinson and Company Blood collection devices containing blood stabilization agent
CN105713092B (zh) 2011-01-06 2019-09-10 戴埃克斯有限公司 血浆前激肽释放酶结合蛋白
US9315811B2 (en) 2011-06-10 2016-04-19 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (KLKB1) expression
WO2012170947A2 (en) 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
FR2983215B1 (fr) 2011-11-28 2013-12-20 Univ Grenoble 1 Dosage de la capacite de controle de c1inh
EP2948479B1 (en) * 2013-01-20 2018-08-01 Dyax Corp. Evaluation and treatment of bradykinin-mediated disorders
AU2014212194A1 (en) * 2013-02-01 2015-09-17 Becton, Dickinson And Company Blood collection devices containing contact pathway inhibition additives
JP6757252B2 (ja) 2013-10-21 2020-09-16 ダイアックス コーポレーション 血漿カリクレイン系バイオマーカーを決定するためのアッセイ
PT3060908T (pt) 2013-10-21 2021-05-27 Dyax Corp Diagnóstico e tratamento de doenças autoimunes
KR102903403B1 (ko) * 2014-01-21 2025-12-24 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도
CA3002747A1 (en) * 2015-10-19 2017-04-27 Dyax Corp. Immunoassay to detect cleaved high molecular weight kininogen
KR102874711B1 (ko) 2015-12-15 2025-10-23 다케다 파머수티컬 컴패니 리미티드 전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법
WO2021094587A1 (en) 2019-11-13 2021-05-20 eV-Technologies Spin-wave based magnetic and/or electro-magnetic field sensing device for dc, rf and millimeter-wave applications
US20230072523A1 (en) 2020-01-28 2023-03-09 Orgenesis Inc. Process and system for acellular therapy

Also Published As

Publication number Publication date
PT3365685T (pt) 2021-03-01
JP7238027B2 (ja) 2023-03-13
AU2016340826C1 (en) 2023-05-04
PL3365685T3 (pl) 2021-08-02
IL312916A (en) 2024-07-01
JP2021167824A (ja) 2021-10-21
ES2973301T3 (es) 2024-06-19
US12493047B2 (en) 2025-12-09
WO2017070170A1 (en) 2017-04-27
CN113655228B (zh) 2025-01-07
KR20240133761A (ko) 2024-09-04
KR102698737B1 (ko) 2024-08-27
CO2018004289A2 (es) 2018-11-22
NZ741448A (en) 2023-10-27
US20210270842A1 (en) 2021-09-02
CN108291917A (zh) 2018-07-17
EP3365685B1 (en) 2020-11-25
PL3839514T3 (pl) 2024-06-10
US10914747B2 (en) 2021-02-09
EP3839514B1 (en) 2023-12-13
AU2016340826B2 (en) 2022-11-24
JP2025081553A (ja) 2025-05-27
CA3002747A1 (en) 2017-04-27
MX2018004763A (es) 2018-09-06
CN113655228A (zh) 2021-11-16
IL258637B1 (en) 2024-06-01
KR20180093897A (ko) 2018-08-22
JP2023078186A (ja) 2023-06-06
EP3839514A1 (en) 2021-06-23
EP4354146A3 (en) 2024-06-05
AU2023200462B2 (en) 2025-06-26
IL258637A (en) 2018-06-28
AU2016340826A1 (en) 2018-04-26
ES2857552T3 (es) 2021-09-29
EA201891002A1 (ru) 2018-11-30
IL258637B2 (en) 2024-10-01
JP7640599B2 (ja) 2025-03-05
BR112018007842A2 (pt) 2019-04-16
MX2023005689A (es) 2023-05-29
US20180306807A1 (en) 2018-10-25
DK3365685T3 (da) 2021-03-01
EP4354146A2 (en) 2024-04-17
EP3365685A1 (en) 2018-08-29
AU2023200462A1 (en) 2023-03-02
CN108291917B (zh) 2021-08-27
JP2019502095A (ja) 2019-01-24

Similar Documents

Publication Publication Date Title
JP7640599B2 (ja) 切断高分子量キニノーゲンを検出するイムノアッセイ
JP7441662B2 (ja) ｐＫａｌ関連疾病の評価、アッセイおよび治療
JP2022188017A (ja) 血漿カリクレイン系バイオマーカーを決定するためのアッセイ
JP2021008483A (ja) ブラジキニン媒介障害の評価および治療
HK40108160A (en) Immunoassay for the detection of cleaved high molecular weight kininogen
HK40055446B (en) Immunoassay to detect cleaved high molecular weight kininogen
HK40055446A (en) Immunoassay to detect cleaved high molecular weight kininogen
HK1259744A1 (en) Immunoassay to detect cleaved high molecular weight kininogen
HK1259744B (en) Immunoassay to detect cleaved high molecular weight kininogen
NZ741448B2 (en) Immunoassay for the detection of cleaved high molecular weight kininogen

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191017

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200818

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210514

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210525

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210623

R150 Certificate of patent or registration of utility model

Ref document number: 6903648

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250